Cabaletta Bio (NASDAQ: CABA) — Perfil da empresa, notícias e dados financeiros
Cabaletta Bio develops T-cell therapies aimed at providing functional cures for autoimmune diseases.
Cabaletta Bio
Cabaletta Bio (NASDAQ:CABA) focuses on developing therapies aimed at providing a functional cure for patients with autoimmune diseases. Its approach centers on utilizing engineered T cell therapies targeting B cell-mediated autoimmune diseases, leveraging its proprietary technology to specifically target and eliminate the cells responsible for disease activity. The company's pipeline includes several projects at various stages of development, targeting a range of autoimmune disorders with the objective of achieving long-term disease remission or functional cure. Cabaletta Bio aims to transform the treatment landscape for autoimmune disease patients, offering new hope through innovative, targeted therapies.
Resumo
Operações
Produtos e/ou serviços de Cabaletta Bio
- DesCAARTes™ platform harnesses Chimeric AutoAntibody Receptor T cells designed to target and eliminate B cells causing autoimmune diseases.
- Dsg3-CAART is a therapy aimed at treating mucosal pemphigus vulgaris by selectively targeting and depleting disease-causing B cells.
- FVIII-CAART seeks to provide a potential treatment for hemophilia A by using engineered T cells to eliminate inhibitors of factor VIII.
- MuSK-CAART therapy is being developed for patients with MuSK myasthenia gravis, targeting specific B cells to alleviate symptoms.
- The collaboration with the University of Pennsylvania explores novel CAART therapies for autoimmune diseases by leveraging genetic engineering expertise and clinical insights.
- CART-TT focuses on T cell-mediated therapies to potentially treat T cell-related autoimmune and inflammatory diseases, offering a unique approach by targeting specific T cell subsets.
equipe executiva do Cabaletta Bio
- Steven A. NichtbergerCo-Founder, Chairman, CEO & President
- David J. ChangChief Medical Officer
- Gwendolyn K. BinderPresident of Science & Technology
- Michael C. MiloneCo-Founder & Co-Chair of Scientific Advisory Board
- Aimee PayneCo-Founder & Co-Chair of Scientific Advisory Board
- Anup MardaChief Financial Officer
- Qing Sarah YuanChief Technology Officer
- Samik BasuChief Scientific Officer
- Michael GerardGeneral Counsel & Secretary
- Heather Harte-HallChief Compliance Officer
Principais indicadores financeiros
Resultados divulgados pela Cabaletta Bio, em USD.
- Cap. de mercado
- 257,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -172,2 mi | -167,9 mi | |
| 0 | -125,1 mi | -115,9 mi | |
| 0 | -74,7 mi | -67,7 mi | |
| 0 | -54,1 mi | -51,8 mi |